Back to Registry

AOD-9604

Also known as: Anti-Obesity Drug 9604, Tyr-hGH177-191, AOD9604

FDA Banned (Category B)

Molecular Formula

C78 H123 N23 O23 S2

Molecular Weight

1,815.1 Da

Half-Life

~4 minutes (plasma)

Sequence

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

Clinical Applications & Evidence

Mechanism of Action

AOD-9604 selectively targets adipose tissue, stimulating lipolysis by activating hormone-sensitive lipase and inhibiting lipogenesis by suppressing acetyl-CoA carboxylase. Its activity is largely mediated through the modulation of β3-adrenergic receptor pathways, though it operates independently of the hGH receptor, preventing systemic IGF-1 elevation and avoiding glucose intolerance.

Investigated Uses

  • Obesity management and localized fat reduction
  • Osteoarthritis intervention and cartilage tissue repair
  • Adjunct oncological delivery in experimental models
Moderate Clinical Data

Regulatory & Safety Status

FDA Status

FDA Banned (Category B)

WADA / Athletic Status

Prohibited in Competition

Known Side Effects

Mild, transient headacheInjection site erythemaDose-dependent gastrointestinal distress (at extreme oral dosages, e.g., 54 mg)

Contraindications

  • Pregnancy
  • Active malignancies
  • Significant hormonal imbalances (without specialist clearance)
  • Inappropriate as a monotherapy for severe metabolic syndrome

Drug Interactions

  • GLP-1 receptor agonists (theoretical complementary metabolic effects)
  • Growth hormone secretagogues (e.g., CJC-1295, Ipamorelin)
  • Tissue repair peptides (e.g., BPC-157, GHK-Cu)
  • Thermogenic agents

Citations & Clinical Trials

PubMed Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone Journal of Endocrinology and Metabolism Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans PubChem PubChem Compound Summary for CID 71300630, Aod-9604 World Anti-Doping Agency WADA Prohibited List Federal Register / FDA List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B